2024 Rome, Italy

I-030 Martin Bergstrand
A workflow for evaluating and optimizing the designs of paediatric studies
Wednesday 10:20-11:50
I-065 Yi-Han Chien
Modelling framework to simulate phenotypic results of antiviral PROTACs
Wednesday 10:20-11:50
I-073 Perrine Courlet
Unlocking efficiency in dose selection based on pharmacokinetic-pharmacodynamic modeling of tumor size data: Insights from Clinical Trial Simulations
Wednesday 10:20-11:50
I-099 Ruben Faelens
Real-world data can estimate pre-exposure prophylactic drug effect in community-acquired respiratory infection trials
Wednesday 10:20-11:50
II-079 Simon Koele
Model-informed trial design for the malaria transmission blocking antibody TB31F
Wednesday 15:20-16:50
II-083 Anders Kristoffersson
Optimal design of a reduced sampling schedule for the characterization of prolactin dynamics in healthy male volunteers and its evaluation to the describe the pharmacodynamic effect of a prolactin antagonist in a single rising dose study
Wednesday 15:20-16:50
III-037 Yomna Nassar
Simulation-based evaluation of combined Likelihood Ratio Test (cLRT) and Multiple Comparison Procedure (MCP) approaches to identify a dose-response relationship in the oncology setting under different study design variables
Thursday 09:50-11:20
III-040 Chiara NicolÚ
Simulating maximum tolerated dose-finding oncology trials using the InSilicoTrials cloud-based platform
Thursday 09:50-11:20
IV-078 Axel Vuorinen
A comparative analysis of Bayesian dose-finding designs incorporating pharmacokinetics information
Thursday 15:00-16:30
IV-109 Xiao Zhang
Assessment of Sample Size Allocation for A Multi-regional Phase 2 Trial: Comparison of Statistical and Dose-Exposure-Response (D-E-R) Approaches
Thursday 15:00-16:30